Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster...
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist...
Author: Yahoo Finance
Read Original Article